Case ReportINTRAVITREAL INJECTION OF PROPRANOLOL FOR THE TREATMENT OF RETINAL CAPILLARY HEMANGIOMA IN A CASE OF VON HIPPEL–LINDAUKarimi, Saeed MD*,†; Nikkhah, Homayoun MD*,†; Ahmadieh, Hamid MD*; Safi, Sare PhD‡ Author Information *Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; †Department of Ophthalmology, Torfeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and ‡Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Reprint requests: Saeed Karimi, MD, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard Street, Boostan 9 Street, Pasdaran Avenue, Tehran 16666, Iran; e-mail: [email protected] None of the authors has any financial/conflicting interests to disclose. Retinal Cases & Brief Reports: Fall 2020 - Volume 14 - Issue 4 - p 305-309 doi: 10.1097/ICB.0000000000000718 Buy Metrics AbstractIn Brief Purpose: The purpose of this study was to evaluate the safety and efficacy of intravitreal propranolol for the management of retinal capillary hemangioma in a patient with Von Hippel–Lindau. Methods: Two intravitreal injections of 50 μg/0.05 mL propranolol were administered 6 weeks apart in the left eye of a 26-year-old patient with bilateral multiple retinal capillary hemangiomas. Safety and response to therapy were evaluated using electroretinogram, fluorescein angiography, and measurement of visual acuity. Laser photocoagulation was performed in the right eye. Results: One month after the second intravitreal injection of propranolol, fluorescein leakage decreased from the tumors located on the optic nerve head and in the inferonasal retinal periphery. Reduction of the retinal capillary hemangioma vascularity and enhancement of its fibrosis associated with the attenuation of the feeder vessel were also observed. Ophthalmic examination showed no adverse effect except for a mild transient vitreous haziness after each injection. Electroretinogram performed 4 weeks after the first injection revealed no retinal toxicity. Conclusion: Intravitreal propranolol showed a therapeutic effect on retinal capillary hemangioma with no short-term adverse effects except a mild transient inflammatory response in a patient with Von Hippel–Lindau. Two intravitreal injections of 50 μg/0.05 mL propranolol were performed, 6 weeks apart, in a case of Von Hippel–Lindau with multiple retinal capillary hemangiomas. One month after the second injection, fluorescein leakage decreased from the tumors and retinal capillary hemangioma vascularity reduced. Ophthalmic examination and electroretinogram showed no adverse effect.